🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Vanda Pharmaceuticals Inc. VNDA R2K

Healthcare · Biotechnology · United States
https://www.vandapharma.com
Company Profile ↓
$5.85
+17.71% 1Y
Mkt Cap$351.79M
P/E-1.44
P/B1.13
52W High$9.56
52W Low$4.19
Book Value$5.54
EPS (TTM)$-4.06

Company Overview

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion. It also develops Fanapt (iloperidone), a long acting injectable (LAI) formulation for the treatment of schizophrenia and hypertension; BysantiTM (milsaperidone), for the acute treatment of manic or mixed episodes associated with bipolar I disorder, and for the treatment of schizophrenia and major depressive disorder; HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder, and pediatric Non-24; PONVORY (ponesimod) to treat psoriasis and ulcerative colitis; and NEREUSTM (tradipitant) for prevention of vomiting induced by GLP-1 receptor agonists, as well as treatment of gastroparesis and atopic dermatitis. In addition, the company's products include Imsidolimab, an IL-36R antagonist to treat generalized pustular psoriasis; VTR-297, for the treatment of hematologic malignancies and onychomycosis, and several oncology indications; and VQW-765, small molecule alpha-7 nicotinic acetylcholine receptor partial agonist for the treatment of social/performance anxiety and psychiatric disorders. Further, it develops cystic fibrosis transmembrane conductance regulator activators and inhibitors; and antisense oligonucleotide molecules. The company was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Recent Developments

  • Dec 2025 Revenue of $216.10M (+8.7% YoY); net profit $-220.47M.
  • Trailing 12 Months Year-on-year growth — revenue +3.4%.
  • 5-Year Trend Long-term compounding — revenue CAGR -5.3%, profit CAGR -1204.5%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-5.29%
1 Year:3.40%

Compounded Profit Growth

5 Years:-1,204.51%
1 Year:-

Stock Price Performance

1 Year:+17.71%
6 Months:-20.19%
3 Months:-18.30%
1 Month:-4.10%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 31% of range
$4.19 $9.56
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)41.48 · Neutral
Price Performance
1M-4.10%
3M-18.30%
6M-20.19%
1Y+17.71%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

No notable strengths flagged.

CONS

  • Revenue declined at -5.3% CAGR over 5 years.
  • Earnings shrank at -1204.5% CAGR over 5 years.
  • Trading 38.8% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-1.44
Industry PE
25.41
Forward P/E
29.25
PEG Ratio
2.23
Book Value
$5.54
Price to Book
1.13
P/S
1.72
EV/EBITDA
-1.21
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-5.29%
Profit 5Y
-1,204.51%
Revenue (YoY)
3.40%
Earnings (YoY)
-

Profitability & Returns

ROCE
-43.97%
ROE
-60.48%
ROA
-18.81%
Profit Margin
-
Op Margin
-97.11%
Gross Margin
94.18%
EPS (Latest Qtr)
$-0.82
EPS (TTM)
$-4.06

Balance Sheet & Liquidity

Debt/Equity
4.66
Quick Ratio
1.91
Current Ratio
2.16
Debt
$13.07M
Total Assets
$433.52M
Current Assets
$293.17M
Working Capital
$202.10M

Ownership

Promoter Holding
6.65%
Chg in Prom Hold
-
FII / Inst Holding
78.25%
Chg in FII Hold
-0.08%

Financial Snapshot

Enterprise Value
$351.79M
Total Revenue (TTM)
$217.78M
EBITDA
$-151.98M
Free Cash Flow
$-83.15M
Operating Cash Flow
$-126.51M
Shares Outstanding
60.14M
Gross Margin
94.18%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 VNDA Vanda Pharmaceuticals Inc. R2K 5.85 -1.44 $351.79M 0.00% -43.97% -60.48% -5.29% -1,204.51%
2 LLY Eli Lilly and Company SPX 1,152.54 41.02 $1.03T 0.61% - 107.46% 7.20% 11.41%
3 JNJ Johnson & Johnson SPX 253.85 29.45 $611.07B 2.23% 14.88% 26.42% 2.43% 4.76%
4 ABBV AbbVie Inc. SPX 244.78 119.40 $432.48B 3.04% 10.47% -129.24% 1.75% -29.06%
5 UNH UnitedHealth Group Incorporated SPX 425.19 32.02 $386.13B 2.27% 9.74% 12.18% 10.40% 5.43%
6 MRK Merck & Co., Inc. SPX 120.78 34.02 $298.31B 2.86% - 18.94% 5.64% 10.01%
7 AZN AstraZeneca PLC NDX 164.50 24.81 $255.12B 1.77% 15.97% 23.48% 9.82% 45.96%
8 TMO Thermo Fisher Scientific Inc. SPX 534.07 29.33 $198.47B 0.40% 8.14% 13.52% 8.81% 12.95%
9 AMGN Amgen Inc. NDXSPX 355.25 24.69 $191.73B 2.84% 18.02% 101.32% 11.77% 5.58%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue -----------43.59M47.35M49.13M-47.71M59.06M59.48M-58.00M62.21M60.31M-62.67M67.90M70.09M60.19M64.39M65.32M62.50M46.06M38.81M47.46M50.47M47.65M50.04M52.59M56.26M57.22M51.72M
Cost of Revenue -----------------------------------3.52M2.74M2.95M3.83M3.16M
Gross Profit 18.87M18.89M22.73M24.36M26.59M28.55M30.87M32.96M37.09M36.38M39.05M38.68M41.74M43.67M46.99M42.22M52.31M52.33M54.34M52.42M55.99M54.04M60.87M------------46.52M49.85M53.30M53.38M48.56M
Operating Expenses -----------------------------------87.55M88.36M84.59M93.74M98.78M
Operating Income -5.46M-9.54M-14.89M-12.47M-4.79M-653.00K-654.00K-7.91M-1.92M-4.92M-2.15M2.44M3.91M6.23M9.15M-2.09M9.89M10.76M4.24M-125.00K9.17M7.74M10.45M10.34M12.37M10.82M-7.67M3.46M3.91M2.00M-2.87M-6.00M-9.23M-10.15M-11.00M-41.03M-38.50M-31.28M-40.35M-50.22M
EBITDA ------------------------------------38.20M-36.75M-29.23M-34.49M-46.70M
Interest Expense ----------------------------------------
Pretax Income ------------------------------------37.37M-34.89M-28.39M-38.00M-48.42M
Tax Provision ------------------------------------7.87M-7.68M-5.80M103.19M143.00K
Net Income -5.39M-9.46M-14.80M-12.36M-4.62M-430.00K-604.00K-7.64M-1.53M-4.55M-1.84M3.07M4.61M7.17M10.36M-612.00K11.53M100.42M4.22M486.00K8.71M5.95M8.19M8.65M9.65M7.77M-6.43M2.57M3.27M3.25M1.52M137.00K-4.15M-4.52M-5.32M-29.49M-27.21M-22.59M-141.19M-48.57M
Diluted EPS --------0.17-0.03-0.10-0.060.090.130.19-0.010.211.840.080.010.160.110.150.150.170.14-0.110.050.060.060.030.00-0.07-0.08-0.09-0.50-0.46-0.38-2.39-0.82
R&D Expense 5.95M9.97M-7.55M6.70M7.29M-10.57M7.65M10.18M-9.42M9.87M11.39M-13.28M10.95M11.35M-15.53M12.90M12.30M-16.13M20.25M19.65M20.97M21.49M24.86M19.24M16.65M16.60M21.15M16.66M16.78M35.71M21.99M22.56M-28.43M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 4.55M35.71M31.27M32.73M33.88M50.16M109.92M146.02M165.08M193.12M227.19M248.17M268.68M254.38M192.64M198.77M216.10M
Cost of Revenue -------------24.28M14.80M11.31M13.04M
Gross Profit -------------230.10M177.84M187.46M203.06M
Operating Expenses -------------223.77M191.80M228.12M354.23M
Operating Income -35.95M8.84M-10.71M-29.18M-21.20M20.06M-40.19M-18.57M-16.90M21.74M22.81M27.24M42.16M6.33M-13.95M-40.66M-151.17M
EBITDA -------------9.06M-9.62M-30.86M-139.25M
Interest Expense -----------------
Pretax Income -------------11.30M6.34M-22.92M-138.65M
Tax Provision -------------5.03M3.83M-4.02M81.83M
Net Income -35.86M7.19M-9.80M-28.62M-21.05M20.19M-39.87M-18.01M-15.57M25.21M115.55M23.34M33.15M6.28M2.51M-18.90M-220.47M
Diluted EPS -1.330.25-0.35-1.01-0.690.55-0.94-0.41-0.350.482.110.420.580.110.04-0.33-3.74
R&D Expense 13.87M12.34M29.00M45.76M28.50M19.23M29.14M29.16M38.55M43.59M48.65M55.58M75.36M85.77M76.82M74.43M109.27M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --213.10M182.62M135.45M143.35M171.70M213.05M210.37M205.43M332.13M483.75M533.46M-634.25M648.44M656.20M488.95M
Current Assets --------------519.29M432.95M438.89M347.26M
Cash & Equivalents 39.08M205.29M42.56M87.92M88.77M64.76M60.90M50.84M40.43M33.63M61.01M45.07M61.03M-135.03M135.82M102.32M84.85M
Inventory --------------1.19M1.36M1.73M1.85M
Receivables --------------33.51M34.16M47.10M54.58M
Total Liabilities --175.37M149.14M125.54M99.22M10.89M80.02M79.04M74.04M56.71M72.80M80.19M-107.05M103.53M117.66M161.76M
Current Liabilities --31.03M31.62M32.26M32.85M7.79M51.32M50.32M70.36M53.02M59.51M65.94M-91.44M87.70M99.98M145.16M
Long Term Debt ------------------
Total Debt --------------11.14M9.40M12.36M12.62M
Total Equity 46.02M23.03M37.73M33.47M9.90M44.12M160.82M133.03M131.33M131.39M275.42M410.94M453.27M-527.20M544.91M538.55M327.19M
Shares Outstanding --------------56.78M57.53M58.31M59.10M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow 169.34M-10.90M-28.41M-44.92M-39.59M----1.98M29.99M45.95M51.77M-31.98M12.80M-15.76M-109.44M
Investing Cash Flow -4.74M-155.62M73.75M45.75M-34.27M----10.23M-109.66M-68.31M-41.50M-49.92M-12.06M-17.43M94.86M
Financing Cash Flow 1.62M3.78M25.00K12.00K49.86M---5.25M107.13M6.26M5.63M-734.00K0-155.00K-2.91M
Capital Expenditure ---275.00K-2.02M-176.00K-769.00K-2.53M-1.41M-1.66M-368.00K-1.02M-1.79M--679.00K-383.00K-490.00K-998.00K
Free Cash Flow ---28.68M-46.93M-39.77M----3.65M29.62M44.93M49.98M-31.30M12.42M-16.25M-110.44M
Net Change in Cash -------------82.64M745.00K-33.34M-17.49M

Ratios (Annual)

Figures in %.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -------------90.5%92.3%94.3%94.0%
Operating Margin % -790.4%24.8%-34.2%-89.2%-62.6%40.0%-36.6%-12.7%-10.2%11.3%10.0%11.0%15.7%2.5%-7.2%-20.5%-70.0%
Net Margin % -788.5%20.1%-31.3%-87.4%-62.1%40.2%-36.3%-12.3%-9.4%13.1%50.9%9.4%12.3%2.5%1.3%-9.5%-102.0%
ROE % -155.7%19.1%-29.3%-288.9%-47.7%12.6%-30.0%-13.7%-11.8%9.2%28.1%5.1%-1.2%0.5%-3.5%-67.4%
ROCE % -4.9%-7.1%-28.3%-19.2%12.2%-24.8%-11.6%-12.5%7.8%5.4%5.8%-1.2%-2.5%-7.3%-44.0%

Shareholding Pattern

Insiders
6.65%
Institutions
78.25%
Public Float
83.82%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 12.10% 7.28M $45.37M
2 Renaissance Technologies, LLC 6.25% 3.76M $23.44M
3 State Street Corporation 5.01% 3.02M $18.80M
4 AIGH Capital Management LLC 4.57% 2.75M $17.15M
5 Vanguard Capital Management LLC 4.13% 2.48M $15.47M
6 Millennium Management Llc 3.13% 1.88M $11.73M
7 Acadian Asset Management. LLC 2.99% 1.80M $11.20M
8 Dimensional Fund Advisors LP 2.95% 1.77M $11.05M
9 AQR Capital Management, LLC 2.67% 1.60M $10.00M
10 Geode Capital Management, LLC 2.40% 1.44M $9.00M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for VNDA

Google News Fri, 10 Jul 2026

Vanda Pharma Stock Rises Pre-Market After FDA Accepts Imsidolimab Filing For Rare Skin Disorder - Stocktwits

<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxPSUR0Tk1tUUNDOTdnbS01NEpnS1lrY3RIeUJLeGhMYjc5bkxqMHl2X1ZPMXQtY1NORjluWG9UR0NEdElvQzZmZ0ZqbUpaYlIyUm5qQnVkTmNwOHhkSWYzVE1MdVNlTFA2QjlQcE5nQUNvRlRNMTNnSm84eFNpdHhtWjlhcVQxN0FKYmR6VG…

Google News Fri, 10 Jul 2026

Vanda Pharmaceuticals plans fireside chat at Boston investor summit - Stock Titan

<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxOVHFUaVJucUFrM2RWaDdxbVN3aGR5MVMzTzVEWU1VUTdtWXIzOTJXY1E0aE1NNUpLc19YU3VMLUV0aW5DYXdhU2JZYUdlZ04xay1FZWRhQy1lTGZ6dGJIS0xmWUliak9tRndqU1NoVjhLbWQyUDZlZWRhc0d2U2dLZEY5ZE16U2x3d0l2bj…

Google News Wed, 06 May 2026

Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results - PR Newswire

<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxPWDVQMWlWM1RNZ3I1Q3hJamJVVWlEaXg0bGlwaFVOUlNKZDQ3cmczMUNRVjNBaDJpdXBnTHI5b2hwcWhHblJuZXM3X0g1S0hQaVlmRnN0QmF2UGo0MVB2ZUpsNEJWS0taRjVkUDRwd3NEdTNyZFNoaDNiRktKZzFPMFA4em5nYUJoT0pfOD…

Google News Wed, 08 Jul 2026

VNDA Stock Gains After-Hours As FDA Grants Rare Pediatric Disease Designation For Experimental Therapy - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxObk95NTJscXQ0eGtmWVhQUXIyQ3kxTmVpNzhxZkxyZ0daVzY0M2lzSUUwQmRXTVJyaU9BSWNfRnZXcHhCcmh3RGdUZjZsQVlmblBXaXQxbXJMZlJsRGo2Z2RtcXE3UWxLNWlXX1dlRDNhNC1XNWhTcmxvcldTd2dqbld3STZKOVZ1ZlozeG…

Google News ue, 10 Mar 2026

$VNDA stock is up 11% today. Here's what we see in our data. - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQMkszWlhqX0xoNkZhSVBrcmpzaVQyUWF5S1RtZy1DUEloMnFyVEVPeHJNemVRVzdFT2NkRFprVkwtSDV1ellXeHJaWWtoUWYtUmZvaGd3QVhienl2MGItZ1NwNF9hWUVzOEdrclZUOUtEalpDaUxQYV9oOTk5Z1lCZnlXUXBnRDRYeTBWUX…

Google News Mon, 23 Feb 2026

Vanda stock’s explosive rally may be more hype than substance - TradingView

<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxPUVgtbnE3VzdnT0pjR3hYZGh3X2FQZ2I5czJ3NDgzUXE3RnZLN0ZSS2N3dGxtR3BGMEczQVB1RS1KLW9Ed19lZXZFOU1mcGc2UUJpTHFtT0JBNXhMWnJRN2hMRGlEcm9kcVFnVmNxT0hVTlVKUmQybFNEOTQ3QWdVVXF5RWY1ZHFDZktvQl…

VNDA — Frequently Asked Questions

What is the current share price of Vanda Pharmaceuticals Inc. (VNDA)?

As of 2026-07-14 21:23 PDT, Vanda Pharmaceuticals Inc. (VNDA) trades at $5.85 on NasdaqGM. Its 52-week range is $4.19 to $9.56.

What is the market capitalisation of VNDA?

Vanda Pharmaceuticals Inc. (VNDA) has a market capitalisation of $351.79M on NasdaqGM.

What is the P/E ratio of VNDA?

VNDA trades at a trailing price-to-earnings (P/E) ratio of -1.44. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 1.13.

What is the return on equity (ROE) of VNDA?

VNDA has a return on equity (ROE) of -60.48%. Its return on capital employed (ROCE) is -43.97%.

Is VNDA a good stock to buy?

This page provides a data-driven analysis of Vanda Pharmaceuticals Inc. (VNDA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space